

# PRODUCT INFORMATION




## Saquinavir (mesylate)

Item No. 9001893

**CAS Registry No.:** 149845-06-7  
**Formal Name:** (2S)-N<sup>1</sup>-[[[(1S,2R)-3-[[[3S,4aS,8aS)-3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinoliny]]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]butanediamide, monomethanesulfonate

**Synonym:** Ro 31-8959/003  
**MF:** C<sub>38</sub>H<sub>50</sub>N<sub>6</sub>O<sub>5</sub> • CH<sub>3</sub>SO<sub>3</sub>H  
**FW:** 767.0  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 206, 239, 291 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Saquinavir (mesylate) is supplied as a crystalline solid. A stock solution may be made by dissolving the saquinavir (mesylate) in the solvent of choice, which should be purged with an inert gas. Saquinavir (mesylate) is soluble in organic solvents such as methanol and DMSO. The solubility of saquinavir (mesylate) in these solvents is approximately 1 mg/ml.

### Description

Saquinavir is an HIV protease inhibitor ( $K_i$ s = 0.12 and < 0.1 nM for HIV-1 and HIV-2 protease, respectively) that exhibits antiviral activity with low cytotoxicity.<sup>1,2</sup> When co-administered with 50 mg/kg ritonavir (Item No. 13872), the bioavailability of 20 mg/kg saquinavir has been shown to increase 325-fold in mice through a mechanism that inhibits its metabolism by CYP3A.<sup>3</sup>

### References

1. Roberts, N.A., Martin, J.A., Kinchington, D., *et al.* Rational design of peptide-based HIV proteinase inhibitors. *Science* **248**(4953), 358-361 (1990).
2. Tucker, T.J., Lumma, W.C., Jr., Payne, L.S., *et al.* A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: Synthesis, enzyme inhibition, and antiviral activity. *J. Med. Chem.* **35**(14), 2525-2533 (1992).
3. Tomaru, A., Takeda-Morishita, M., Banba, H., *et al.* Analysis of the pharmacokinetic boosting effects of ritonavir on oral bioavailability of drugs in mice. *Drug Metab. Pharmacokinet.* **28**(2), 144-152 (2013).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/18/2019

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM